DISCLOSUREAPPENDIXATTHEBACKOFTHISREPORTCONTAINSIMPORTANTDISCLOSURES,ANALYSTCERTIFICATIONS,LEGALENTITYDISCLOSUREANDTHESTATUSOFNON-USANALYSTS.USDisclosure:CreditSuissedoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethattheFirmmayhaveaconflictofinterestthatcouldaffecttheobjectivityofthisreport.Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.19June2019Americas/UnitedStatesEquityResearchHealthcareGlobalPharmaceuticals&MedicalDevicesCONFERENCECALLResearchAnalystsVamilDivan,MD2125385394vamil.divan@credit-suisse.comMattMiksic2123254381matt.miksic@credit-suisse.comTrungHuynh442078882102trung.huynh@credit-suisse.comEuropeanPharmaTeam442078880304creditsuisse.pharmateam@credit-suisse.comMichaelV.MorabitoPh.D.2123257298michael.morabito@credit-suisse.comUyEar2123251729uy.ear@credit-suisse.comVikChopra2123251749vik.chopra@credit-suisse.comInancCaner2123255051inanc.caner@credit-suisse.comTranscriptfromDiabetesExpertCallWithInvestorsPostADA2019FollowingADA,wehostedaninvestorcallwithDr.UtpalPajvani,anendocrinologistandanAssociateProfessorofMedicineatColumbiaUniversityMedicalCenter.Weprovidethetranscriptfromthecallherein.19June2019GlobalPharmaceuticals&MedicalDevices2CreditSuisseSecurities,LLCJune14,201910:00a.m.ESTOperator:Goodday,ladiesandgentlemen,andthankyouforstandingby.WelcometotheCreditSuisseADAWrapUpConferenceCall.Atthistime,allparticipantsareinalisten-onlymodetopreventbackgroundnoise.Ifyouneedassistanceatanytime,justpress“star”and“zero”toreachanoperator.Later,wewillhaveaquestionandanswersession.Andnow,it’smypleasuretoturnthecalltoVamilDivan.VamilDivan:Great.Thankssomuch,operator.Thanks,everyone,forjoiningusonthecall.ThisisVamilDivan.I’mtheU.S.pharmaanalysthereatCreditSuisse.AlsojoinedbysomeofmycolleaguesontheCSside.WehaveMattMiksicbasedhereintheU.S.coveringMedicalDevices,andalsoTrungHuynhfromourteaminEuropecoveringEuropeanpharma.Andobviouslythetopicoftoday’scallistogooversomeoftheda...
